Shandong Lukang Pharmaceutical Co Ltd
Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company provides analgesics and antipyretics; gastrointestinal; endocrine; cardio-cerebrovascular; anti-infective; and other human formulation products. It offers human and veterinary active pharmaceutical ingredient; veterinary formulation; bio-pesticides; and amino acid. The company also exports its produ… Read more
Shandong Lukang Pharmaceutical Co Ltd (600789) - Net Assets
Latest net assets as of September 2025: CN¥4.10 Billion CNY
Based on the latest financial reports, Shandong Lukang Pharmaceutical Co Ltd (600789) has net assets worth CN¥4.10 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.82 Billion) and total liabilities (CN¥4.71 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.10 Billion |
| % of Total Assets | 46.56% |
| Annual Growth Rate | 11.11% |
| 5-Year Change | 20.91% |
| 10-Year Change | 113.17% |
| Growth Volatility | 25.3 |
Shandong Lukang Pharmaceutical Co Ltd - Net Assets Trend (1993–2024)
This chart illustrates how Shandong Lukang Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shandong Lukang Pharmaceutical Co Ltd (1993–2024)
The table below shows the annual net assets of Shandong Lukang Pharmaceutical Co Ltd from 1993 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.06 Billion | +8.56% |
| 2023-12-31 | CN¥3.74 Billion | +6.68% |
| 2022-12-31 | CN¥3.51 Billion | +3.18% |
| 2021-12-31 | CN¥3.40 Billion | +1.19% |
| 2020-12-31 | CN¥3.36 Billion | +5.92% |
| 2019-12-31 | CN¥3.17 Billion | +3.26% |
| 2018-12-31 | CN¥3.07 Billion | +46.35% |
| 2017-12-31 | CN¥2.10 Billion | +5.89% |
| 2016-12-31 | CN¥1.98 Billion | +4.03% |
| 2015-12-31 | CN¥1.91 Billion | +26.66% |
| 2014-12-31 | CN¥1.50 Billion | -7.99% |
| 2013-12-31 | CN¥1.63 Billion | +1.73% |
| 2012-12-31 | CN¥1.61 Billion | -5.11% |
| 2011-12-31 | CN¥1.69 Billion | +1.01% |
| 2010-12-31 | CN¥1.68 Billion | +8.31% |
| 2009-12-31 | CN¥1.55 Billion | +3.14% |
| 2008-12-31 | CN¥1.50 Billion | +2.78% |
| 2007-12-31 | CN¥1.46 Billion | +2.69% |
| 2006-12-31 | CN¥1.42 Billion | -5.10% |
| 2005-12-31 | CN¥1.50 Billion | +0.21% |
| 2004-12-31 | CN¥1.50 Billion | -7.40% |
| 2003-12-31 | CN¥1.61 Billion | +28.18% |
| 2002-12-31 | CN¥1.26 Billion | +8.45% |
| 2001-12-31 | CN¥1.16 Billion | +2.77% |
| 2000-12-31 | CN¥1.13 Billion | +2.78% |
| 1999-12-31 | CN¥1.10 Billion | -1.82% |
| 1998-12-31 | CN¥1.12 Billion | +26.58% |
| 1997-12-31 | CN¥885.05 Million | +120.24% |
| 1996-12-31 | CN¥401.85 Million | +28.40% |
| 1995-12-31 | CN¥312.96 Million | +68.13% |
| 1994-12-31 | CN¥186.15 Million | +20.24% |
| 1993-12-31 | CN¥154.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Lukang Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 205360.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.14 Billion | 28.97% |
| Common Stock | CN¥898.67 Million | 22.94% |
| Other Components | CN¥1.88 Billion | 48.10% |
| Total Equity | CN¥3.92 Billion | 100.00% |
Shandong Lukang Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Shandong Lukang Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vimian Group AB (publ)
PINK:VIMGF
|
$829.05 Million |
|
ADTRAN Inc
NASDAQ:ADTN
|
$829.20 Million |
|
Brooks Automation Inc.
LSE:0HQ1
|
$829.24 Million |
|
Basic-Fit N.V
PINK:BSFFF
|
$829.31 Million |
|
Yantai Changyu Pioneer Wine Co Ltd
SHE:000869
|
$828.59 Million |
|
Jiangsu Yinhe Electronics Co Ltd
SHE:002519
|
$828.41 Million |
|
Changchun UP Optotech Co Ltd
SHE:002338
|
$827.73 Million |
|
Thai Union Group PCL
BK:TU
|
$827.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Lukang Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,611,695,000 to 3,918,185,000, a change of 306,490,000 (8.5%).
- Net income of 394,615,736 contributed positively to equity growth.
- Dividend payments of 233,491,000 reduced retained earnings.
- Other factors increased equity by 145,365,264.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥394.62 Million | +10.07% |
| Dividends Paid | CN¥233.49 Million | -5.96% |
| Other Changes | CN¥145.37 Million | +3.71% |
| Total Change | CN¥- | 8.49% |
Book Value vs Market Value Analysis
This analysis compares Shandong Lukang Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 45.20x to 1.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-12-31 | CN¥0.18 | CN¥8.29 | x |
| 1994-12-31 | CN¥0.22 | CN¥8.29 | x |
| 1995-12-31 | CN¥0.26 | CN¥8.29 | x |
| 1996-12-31 | CN¥0.48 | CN¥8.29 | x |
| 1997-12-31 | CN¥1.05 | CN¥8.29 | x |
| 1998-12-31 | CN¥1.33 | CN¥8.29 | x |
| 1999-12-31 | CN¥1.30 | CN¥8.29 | x |
| 2000-12-31 | CN¥1.34 | CN¥8.29 | x |
| 2001-12-31 | CN¥1.38 | CN¥8.29 | x |
| 2002-12-31 | CN¥2.35 | CN¥8.29 | x |
| 2003-12-31 | CN¥3.02 | CN¥8.29 | x |
| 2004-12-31 | CN¥2.80 | CN¥8.29 | x |
| 2005-12-31 | CN¥2.80 | CN¥8.29 | x |
| 2006-12-31 | CN¥2.49 | CN¥8.29 | x |
| 2007-12-31 | CN¥2.08 | CN¥8.29 | x |
| 2008-12-31 | CN¥1.94 | CN¥8.29 | x |
| 2009-12-31 | CN¥1.87 | CN¥8.29 | x |
| 2010-12-31 | CN¥2.15 | CN¥8.29 | x |
| 2011-12-31 | CN¥2.56 | CN¥8.29 | x |
| 2012-12-31 | CN¥2.01 | CN¥8.29 | x |
| 2013-12-31 | CN¥2.16 | CN¥8.29 | x |
| 2014-12-31 | CN¥1.90 | CN¥8.29 | x |
| 2015-12-31 | CN¥1.76 | CN¥8.29 | x |
| 2016-12-31 | CN¥2.45 | CN¥8.29 | x |
| 2017-12-31 | CN¥2.64 | CN¥8.29 | x |
| 2018-12-31 | CN¥3.45 | CN¥8.29 | x |
| 2019-12-31 | CN¥3.43 | CN¥8.29 | x |
| 2020-12-31 | CN¥3.53 | CN¥8.29 | x |
| 2021-12-31 | CN¥3.70 | CN¥8.29 | x |
| 2022-12-31 | CN¥3.65 | CN¥8.29 | x |
| 2023-12-31 | CN¥4.03 | CN¥8.29 | x |
| 2024-12-31 | CN¥4.37 | CN¥8.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Lukang Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.07%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.33%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 2.32x
- Recent ROE (10.07%) is above the historical average (5.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | 20.86% | 8.14% | 0.98x | 2.62x | CN¥16.81 Million |
| 1994 | 32.89% | 14.09% | 0.97x | 2.42x | CN¥42.60 Million |
| 1995 | 29.68% | 13.53% | 0.77x | 2.84x | CN¥43.74 Million |
| 1996 | 21.33% | 14.35% | 0.76x | 1.96x | CN¥45.53 Million |
| 1997 | 10.68% | 13.69% | 0.52x | 1.50x | CN¥6.06 Million |
| 1998 | 5.25% | 10.45% | 0.36x | 1.39x | CN¥-53.16 Million |
| 1999 | 4.21% | 7.81% | 0.33x | 1.63x | CN¥-63.72 Million |
| 2000 | 5.03% | 8.10% | 0.31x | 2.01x | CN¥-56.24 Million |
| 2001 | 6.07% | 9.14% | 0.32x | 2.05x | CN¥-45.71 Million |
| 2002 | 7.66% | 9.28% | 0.44x | 1.87x | CN¥-29.48 Million |
| 2003 | 3.35% | 5.56% | 0.36x | 1.67x | CN¥-107.37 Million |
| 2004 | -6.18% | -8.99% | 0.38x | 1.80x | CN¥-241.89 Million |
| 2005 | 0.33% | 0.43% | 0.45x | 1.73x | CN¥-144.87 Million |
| 2006 | -6.79% | -8.67% | 0.46x | 1.71x | CN¥-238.67 Million |
| 2007 | 1.78% | 1.85% | 0.56x | 1.72x | CN¥-119.98 Million |
| 2008 | 2.38% | 2.03% | 0.69x | 1.69x | CN¥-112.82 Million |
| 2009 | 2.47% | 1.93% | 0.78x | 1.63x | CN¥-114.84 Million |
| 2010 | 7.86% | 5.90% | 0.73x | 1.83x | CN¥-35.25 Million |
| 2011 | 0.90% | 0.64% | 0.67x | 2.09x | CN¥-151.26 Million |
| 2012 | -8.81% | -5.72% | 0.59x | 2.62x | CN¥-285.70 Million |
| 2013 | 0.71% | 0.49% | 0.54x | 2.67x | CN¥-141.89 Million |
| 2014 | -8.89% | -5.42% | 0.57x | 2.90x | CN¥-266.10 Million |
| 2015 | 0.44% | 0.33% | 0.60x | 2.22x | CN¥-173.12 Million |
| 2016 | 1.57% | 1.16% | 0.60x | 2.25x | CN¥-156.43 Million |
| 2017 | 5.83% | 4.39% | 0.50x | 2.66x | CN¥-81.55 Million |
| 2018 | 5.51% | 4.85% | 0.51x | 2.24x | CN¥-131.33 Million |
| 2019 | 4.01% | 3.25% | 0.53x | 2.35x | CN¥-180.86 Million |
| 2020 | 7.09% | 5.42% | 0.58x | 2.26x | CN¥-93.52 Million |
| 2021 | 2.74% | 1.81% | 0.63x | 2.39x | CN¥-236.30 Million |
| 2022 | 4.11% | 2.46% | 0.64x | 2.60x | CN¥-197.67 Million |
| 2023 | 6.82% | 4.00% | 0.70x | 2.44x | CN¥-115.00 Million |
| 2024 | 10.07% | 6.33% | 0.69x | 2.32x | CN¥2.80 Million |
Industry Comparison
This section compares Shandong Lukang Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,075,411,249
- Average return on equity (ROE) among peers: 9.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Lukang Pharmaceutical Co Ltd (600789) | CN¥4.10 Billion | 20.86% | 1.15x | $828.77 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $902.62 Million | 5.17% | 3.60x | $597.12 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.15 Billion | 3.98% | 1.16x | $313.25 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.35 Billion | 7.54% | 0.22x | $3.25 Billion |
| Wedge Industrial Co Ltd (000534) | $643.84 Million | 3.65% | 1.07x | $1.71 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $247.96 Million | 10.36% | 0.27x | $5.35 Billion |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.78 Million | 10.37% | 0.50x | $315.24 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.16 Billion | 6.95% | 1.96x | $416.82 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $720.42 Million | 13.93% | 0.65x | $1.93 Billion |
| Renhe Pharmacy Co Ltd (000650) | $857.16 Million | 19.68% | 0.24x | $748.56 Million |
| Changchun High & New Technology Industries Group Inc (000661) | $451.02 Million | 11.10% | 0.94x | $3.34 Billion |